Events in CNS Tumor Pathology Post-2016 WHO CNS: cIMPACT-NOW Updates and Other Advancements: A Comprehensive Review Plus a Summary of the Salient Features of 2021 WHO CNS 5

Introduction The 2016 World Health Organization Classification (WHO) of Tumors of the Central Nervous System (CNS) represented a major change. It recommended an “integrated diagnosis” comprising histologic and molecular information facilitating a more precise diagnosis of specific CNS tumors. Its goal was to provide greater diagnostic precision and reproducibility resulting in more clinical relevance and predictive value, ultimately leading to better patient care. Advances in molecular classification, mostly resulting from DNA methylation array profiling of CNS tumors, were occurring at a very rapid pace and required more rapid integration into clinical practice. Methods cIMPACT-NOW updates and other recent papers plus salient features of 2021 WHO CNS5 in this comprehensive write-up were reviewed. Results CNS tumor classification needs to be updated at a rapid pace and mechanisms put into place to guide diagnosticians and clinicians in the interim period if major changes in the classification of tumor types came to light. Recognizing the need to integrate these into clinical practice more rapidly and without inordinate delay, the International Society of Neuropathology (ISN) 2016 sponsored an initiative called cIMPACT-NOW. Discussion and/or Conclusion Goal of cIMPACT-NOW was to provide clarification regarding contentious issues arising in the wake of the 2016 WHO CNS update as well as report new advancements in molecular classification of CNS tumors and new tumor entities emerging as a result of these advancements. cIMPACT-NOW updates: It thus laid the foundation for the 5th edition of the WHO Classification of CNS tumors (2021 WHO CNS 5). We have discussed cIMPACT updates in detail in this review. In addition, molecular diagnostics including DNA methylation-based classification of CNS tumors and the practical use of molecular classification in the prognostication and treatment of CNS tumors is discussed. Finally, the salient features of the new CNS tumor classification are summarized.

[1]  P. Wen,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications. , 2021, Neuro-oncology.

[2]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[3]  R. McLendon,et al.  Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. , 2021, Neuro-oncology.

[4]  E. Rushing WHO classification of tumors of the nervous system: preview of the upcoming 5th edition , 2021, memo - Magazine of European Medical Oncology.

[5]  P. Wesseling,et al.  The cIMPACT-NOW updates and their significance to current neuro-oncology practice. , 2020, Neuro-oncology practice.

[6]  C. Hawkins,et al.  Diffuse midline glioma: review of epigenetics , 2020, Journal of Neuro-Oncology.

[7]  K. Aldape,et al.  cIMPACT‐NOW update 7: advancing the molecular classification of ependymal tumors , 2020, Brain pathology.

[8]  T. Komori,et al.  Diffuse gliomas to date and beyond 2016 WHO Classification of Tumours of the Central Nervous System , 2020, International Journal of Clinical Oncology.

[9]  Edward S. Kim,et al.  Relationship between MLH1, PMS2, MSH2 and MSH6 gene‐specific alterations and tumor mutational burden in 1057 microsatellite instability‐high solid tumors , 2020, International journal of cancer.

[10]  D. Brat,et al.  The Essentials of Molecular Testing in CNS Tumors: What to Order and How to Integrate Results , 2020, Current Neurology and Neuroscience Reports.

[11]  Pieter Wesseling,et al.  cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and grading , 2020, Brain pathology.

[12]  Trevor J Pugh,et al.  Clinical impact of combined epigenetic and molecular analysis of pediatric low grade gliomas. , 2020, Neuro-oncology.

[13]  C. Horbinski,et al.  The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas , 2020, Acta Neuropathologica Communications.

[14]  G. Reifenberger,et al.  cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas , 2020, Acta Neuropathologica.

[15]  M. Kool,et al.  Diffuse glioneuronal tumour with oligodendroglioma‐like features and nuclear clusters (DGONC) – a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14 , 2019, Neuropathology and applied neurobiology.

[16]  V. Hovestadt,et al.  Medulloblastomics revisited: biological and clinical insights from thousands of patients , 2019, Nature Reviews Cancer.

[17]  P. Northcott,et al.  Medulloblastoma genomics in the modern molecular era , 2019, Brain pathology.

[18]  Wei-wei Wang,et al.  IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations , 2019, Brain pathology.

[19]  David T. W. Jones,et al.  Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities , 2019, Acta Neuropathologica Communications.

[20]  M. J. van den Bent,et al.  Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. , 2019, Neuro-oncology.

[21]  T. Komori The anticipated revision of the grading criteria for adult isocitrate dehydrogenase-mutant diffuse glioma within the neuro-oncology community. , 2019, Neuro-oncology.

[22]  E. Holland,et al.  Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma. , 2019, Journal of neuropathology and experimental neurology.

[23]  David T. W. Jones,et al.  MYCN amplification drives an aggressive form of spinal ependymoma , 2019, Acta Neuropathologica.

[24]  F. Ducray,et al.  PL1.1 CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas , 2019, Neuro-Oncology.

[25]  F. Ducray,et al.  CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. , 2019, Neuro-oncology.

[26]  Susan M. Chang,et al.  The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. , 2019, Neuro-oncology.

[27]  Pieter Wesseling,et al.  cIMPACT‐NOW: a practical summary of diagnostic points from Round 1 updates , 2019, Brain pathology.

[28]  G. Reifenberger,et al.  Data Sets for the Reporting of Tumors of the Central Nervous System. , 2019, Archives of pathology & laboratory medicine.

[29]  P. Wesseling,et al.  Molecular pathology of tumors of the central nervous system , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  H. Noushmehr,et al.  Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks , 2019, Neuro-oncology advances.

[31]  J. Crawford,et al.  Nivolumab in the Treatment of Recurrent or Refractory Pediatric Brain Tumors: A Single Institutional Experience , 2019, Journal of pediatric hematology/oncology.

[32]  T. Merchant,et al.  Molecular Grouping and Outcomes of Young Children with Newly Diagnosed Ependymoma Treated on the Multi-Institutional SJYC07 Trial. , 2019, Neuro-oncology.

[33]  D. Brat,et al.  What Every Neuropathologist Needs to Know: Update on cIMPACT-NOW. , 2019, Journal of neuropathology and experimental neurology.

[34]  E. Holland,et al.  Targeted copy number analysis outperforms histologic grading in predicting patient survival for WHO grades II/III IDH-mutant astrocytomas. , 2019, Neuro-oncology.

[35]  R. McLendon,et al.  Genomic analysis demonstrates that histologically-defined astroblastomas are molecularly heterogeneous and that tumors with MN1 rearrangement exhibit the most favorable prognosis , 2019, Acta Neuropathologica Communications.

[36]  David T. W. Jones,et al.  cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation , 2019, Acta Neuropathologica.

[37]  Y. Sonoda,et al.  Practical procedures for the integrated diagnosis of astrocytic and oligodendroglial tumors , 2019, Brain Tumor Pathology.

[38]  Martin Sill,et al.  Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre , 2019, Acta Neuropathologica Communications.

[39]  B. Jean-Claude,et al.  Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities , 2019, Front. Oncol..

[40]  A. Jakola,et al.  Clinical Presentation, Natural History, and Prognosis of Diffuse Low-Grade Gliomas. , 2019, Neurosurgery clinics of North America.

[41]  P. Wen,et al.  Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma , 2018, Nature Medicine.

[42]  M. Kool,et al.  Integrated molecular characterization of IDH‐mutant glioblastomas , 2018, Neuropathology and applied neurobiology.

[43]  I. Shmulevich,et al.  Epigenetic profiling for the molecular classification of metastatic brain tumors , 2018, Nature Communications.

[44]  G. Reifenberger,et al.  cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV” , 2018, Acta Neuropathologica.

[45]  Stefan M. Pfister,et al.  Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma , 2018, Acta Neuropathologica.

[46]  G. Reifenberger,et al.  DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment , 2018, Neuro-oncology.

[47]  Martin Sill,et al.  Heterogeneity within the PF-EPN-B ependymoma subgroup , 2018, Acta Neuropathologica.

[48]  Martin Sill,et al.  Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience , 2018, Acta Neuropathologica.

[49]  M. Snuderl,et al.  Genetic and Epigenetic Features of Rapidly Progressing IDH-Mutant Astrocytomas , 2018, Journal of neuropathology and experimental neurology.

[50]  David T. W. Jones,et al.  Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas , 2018, Acta Neuropathologica.

[51]  David T. W. Jones,et al.  Novel, improved grading system(s) for IDH-mutant astrocytic gliomas , 2018, Acta Neuropathologica.

[52]  Pieter Wesseling,et al.  cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant , 2018, Acta Neuropathologica.

[53]  David T. W. Jones,et al.  Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations , 2018, Acta Neuropathologica.

[54]  Till Acker,et al.  DNA methylation-based classification of central nervous system tumours , 2018, Nature.

[55]  F. Rodriguez,et al.  Recurrent copy number alterations in low‐grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation , 2018, Brain pathology.

[56]  D. Louis,et al.  cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC) , 2018, Acta Neuropathologica.

[57]  Hideo Nakamura,et al.  Prognostic relevance of genetic alterations in diffuse lower-grade gliomas , 2018, Neuro-oncology.

[58]  A. Chinnaiyan,et al.  Circumscribed/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas , 2018, Acta Neuropathologica.

[59]  P. Varlet,et al.  Co‐occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma , 2018, Brain pathology.

[60]  T. Maruyama,et al.  Brainstem pilocytic astrocytoma with H3 K27M mutation: case report. , 2017, Journal of neurosurgery.

[61]  B. Kleinschmidt-DeMasters,et al.  H3 K27M Mutation in Gangliogliomas can be Associated with Poor Prognosis , 2017, Brain pathology.

[62]  G. Reifenberger,et al.  cIMPACT‐NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification , 2017, Brain pathology.

[63]  W. Dinjens,et al.  Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification , 2017, Acta Neuropathologica.

[64]  N. Kitchen,et al.  Dabrafenib and trametinib in BRAFV600E mutated glioma. , 2017, CNS oncology.

[65]  James Suh,et al.  Comprehensive Genomic Profiling of 282 Pediatric Low‐ and High‐Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures , 2017, The oncologist.

[66]  J. Huse,et al.  Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy , 2017, Neuro-oncology.

[67]  D. Johnston,et al.  Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome , 2017, Acta Neuropathologica.

[68]  P. Varlet,et al.  Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours , 2017, Acta Neuropathologica Communications.

[69]  Satoshi O. Suzuki,et al.  Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution , 2017, Brain Tumor Pathology.

[70]  T. Kondo,et al.  Molecular mechanisms involved in gliomagenesis , 2017, Brain Tumor Pathology.

[71]  K. Aldape,et al.  The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants , 2016, Acta Neuropathologica.

[72]  David T. W. Jones,et al.  Evidence of H3 K27M mutations in posterior fossa ependymomas , 2016, Acta Neuropathologica.

[73]  J. Golfinos,et al.  Pilocytic astrocytoma and glioneuronal tumor with histone H3 K27M mutation , 2016, Acta Neuropathologica Communications.

[74]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[75]  M. Papotti,et al.  Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas , 2016, Oncotarget.

[76]  Steven J. M. Jones,et al.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.

[77]  Heather L. Mulder,et al.  Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology , 2016, Acta Neuropathologica.

[78]  D. Louis,et al.  The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas , 2016, Journal of neuropathology and experimental neurology.

[79]  G. Reifenberger,et al.  Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy , 2016, Acta Neuropathologica.

[80]  Steven J. M. Jones,et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.

[81]  Pieter Wesseling,et al.  IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO , 2015, Acta Neuropathologica.

[82]  Gelareh Zadeh,et al.  Glioblastoma: pathology, molecular mechanisms and markers , 2015, Acta Neuropathologica.

[83]  Gary D Bader,et al.  Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. , 2015, Cancer cell.

[84]  Arie Perry,et al.  CDKN2A Loss Is Associated With Shortened Overall Survival in Lower-Grade (World Health Organization Grades II–III) Astrocytomas , 2015, Journal of neuropathology and experimental neurology.

[85]  David T. W. Jones,et al.  Pilocytic astrocytoma: pathology, molecular mechanisms and markers , 2015, Acta Neuropathologica.

[86]  D. Merico,et al.  BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  Gabriele Schackert,et al.  Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups , 2015, Acta Neuropathologica.

[88]  J. Grill,et al.  Long survival in a child with a mutated K27M-H3.3 pilocytic astrocytoma , 2015, Annals of clinical and translational neurology.

[89]  Susan M. Chang,et al.  Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment , 2015, Acta Neuropathologica.

[90]  K. Aldape,et al.  IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas , 2015, Acta Neuropathologica.

[91]  Volker Hovestadt,et al.  Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity , 2015, Acta Neuropathologica.

[92]  Pieter Wesseling,et al.  International Society of Neuropathology‐Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading , 2014, Brain pathology.

[93]  Gary D Bader,et al.  Epigenomic alterations define lethal CIMP-positive ependymomas of infancy , 2014, Nature.

[94]  D. Brat,et al.  PDGFRA Amplification is Common in Pediatric and Adult High‐Grade Astrocytomas and Identifies a Poor Prognostic Group in IDH1 Mutant Glioblastoma , 2013, Brain pathology.

[95]  Dongfang Li,et al.  Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance , 2013, Nature Genetics.

[96]  Heather L. Mulder,et al.  Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas , 2013, Nature Genetics.

[97]  T. Merchant,et al.  Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas , 2012, Acta Neuropathologica.

[98]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas , 2012, Acta Neuropathologica.

[99]  Gary D Bader,et al.  Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. , 2011, Cancer cell.

[100]  Richard G Grundy,et al.  Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts , 2011, Journal of Negative Results in BioMedicine.

[101]  Tracy T Batchelor,et al.  A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. , 2006, Cancer research.

[102]  R. Barnard,et al.  The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.

[103]  Yon E.udolpii On Tumours , 1864, The British and Foreign Medico-Chirurgical Review.